Pyrotinib combined with trastuzumab and chemotherapy in the treatment of HER2-positive metastatic breast cancer after the progression of trastuzumab therapy
Trastuzumab combined with pyrotinib and chemotherapy showed clinical benefits and acceptable tolerance in HER2-positive MBC patients previously treated with trastuzumab. Thus, these combination regimens may be potential options for such patients.
Authors
- Hongge Wu
- Yue Hu (ORCID: https://orcid.org/0000-0002-4567-4223)
- Huijie Liu (ORCID: https://orcid.org/0000-0003-4821-5986)
- Jie Xiong (ORCID: https://orcid.org/0000-0002-6350-5853)
- Yuehua Wang (ORCID: https://orcid.org/0000-0002-7650-6417)
- Xiangping Mei
- Linka Xie
- Jing Yao (ORCID: https://orcid.org/0009-0003-8632-518X)
Institutions
- Xiangyang Central Hospital (CN)
- Wuhan Union Hospital (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Journal of the Formosan Medical Association
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.jfma.2025.03.003
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Natural Science Foundation of China